



# Personalized medicine in patients with colorectal liver metastases

Mohammad Hossein Hooshangi <sup>1\*</sup>, Aynaz Nouri <sup>2</sup>, Fatemeh Soleymani Lashkenari <sup>3</sup>

1. School of Pharmacy, Guilan University of Medical Sciences, Rasht, Iran. \*Corresponding Author. [mhhooshangi5@gmail.com](mailto:mhhooshangi5@gmail.com)
2. Amity Institute of Pharmacy, Amity University, Noida, UP, India.
3. Faculty of Sciences, University of Guilan, Rasht, Iran.

Use your device to scan and read the article online



**Citation** Hooshangi MH, Nouri A, Soleymani Lashkenari F, Personalized medicine in patients with colorectal liver metastases. Journal of Pharmacoeconomics and Pharmaceutical Management. 2022; 8(3):44-49

**Running Title** Personalized medicine in patients with CRLM

**Article Type** Review Article

## Article info:

**Received:** 01.11.2021

**Revised:** 30.08.2022

**Accepted:** 17.09.2022

## License Statement

This work is licensed under a Creative Commons Attribution NonCommercial 4.0 International license

(<https://creativecommons.org/licenses/by-nc/4.0/>).

Non-commercial uses of the work are permitted, provided the original work is properly cited

Copyright © 2022 The Authors.

## Publisher

Tehran University of Medical Sciences

## ABSTRACT

**Background:** The precision Medicine initiative is a new research exertion intending to offer personalized medicine for many illnesses, including cancer. The purpose of the current article is to offer novel insights into the role of personalized medicine in patients with colorectal liver metastases (CRLM).

**Methods:** An assess the writing in regards to personalized medication and cancer in patients with colorectal liver metastases was performed in the MEDLINE/PubMed database.

**Results:** Surgical resection remains the main hope for a cure of CRLM. Worked on surgical scheme to improve remnant liver volume are as of late presented and making progress. Following resection of CRLM scoring methods have been evolved by amalgamated certain preoperative factors, for example, microsatellite instability KRAS expression and sensitivity to immunotherapy with programmed Death-1 inhibitor.

**Conclusion:** Multidisciplinary management of patients with CRLM has particularly added to survival. While these significant developments have described the most recent quite a few years, future advances for patients with CRLM will rely upon a superior comprehension of genomics and molecular biology to promote the portrayal of a specific tumor "identity" so that individualized therapy for each CRLM patient turns into the rule, and not the exception.

**Keywords:** personalized medicine, cancer, liver cancer, Multidisciplinary management in cancer.



## Introduction

Genetics and molecular profiling of tumor specimens has uncovered likely focuses for personalized anticancer therapy and seen a shift toward an arising molecular taxonomy of cancer. [1] Genomics and molecular biology are given uncommon opportunities to uncover the basic genetic pathways driving malignancy and are speeding up the advancement of personalized treatment methodologies. In the same way as other tumors, colorectal liver metastasis (CRLM) is an uncommon heterogeneous malignant disease presumably because of variations in genomic profile, molecular and signal transduction network, and microenvironment discrepancies. [2] Multidisciplinary approach for liver metastases at present addresses the best methodology in the management of patients with colorectal cancer.

The role of a surgery in CRLM patients:

Surgical resection remains the main hope for a cure of CRLM. In spite of the fact that surgery is related to a low-operative mortality of 1%-2%, [3] long-term survival is variable relying upon the period from which the information is variable for and the underlying patient population. [4] R0 resection, joined with modern systemic therapy, stays the foundation for increasing 5-year survival that presentational approaches 50%-60%. [5] Worked on surgical strategies to optimize remainder liver volume like portal vein embolization (PVE), two-stage hepatectomy, Associating Liver Partition and Portal Vein Ligation for Staged hepatectomy, and the widespread adoption of parenchymal sparing resection have permitted hepatectomy to be presented to more patients who have a greater tumor burden and more widespread disease. [6-8] notwithstanding this, numerous patients are not candidates for resection due to clinical or technical reasons (severe comorbidities, extensive intrahepatic multifocal disease, unresectable extrahepatic disease, etc.). [9] Furthermore, even among patients resected for cure, disease repeat happens in up to 70% of patients, frequently during the initial three years after surgery. [4] At the point when recurrence is intrahepatic just, repeat hepatic resection might be feasible, in any case, "true" long-term cure stays hard to accomplish. [8]

## Materials and Method

An assess the writing in regards to personalized medication and cancer in patient with colorectal liver metastases was performed in the MEDLINE/PubMed database.

## Data analysis

Following resection of CRLM, morphologic criteria are normally used to anticipate which patients have more aggressive disease and are, accordingly, bound to experience recurrence and have worse long-term survival. Scoring system depends on these clinicopathological factors generally have included preoperative factors, for example, primary tumor stage, carcinoembryonic antigen levels, number of liver metastases, presence of extrahepatic disease, as well as other factors. [10] In spite of the fact that scoring systems have developed by consolidating certain preoperative factors, these have been conflicting in precisely deciding anticipation. Microsatellite instability (MSI) is considered a promising component that might could potentially enable identification of patients who might profit from the chemotherapy and, specifically, immunotherapy with PD-1 inhibitor therapy. [11] The prescient worth of the MSI status in the palliative treatment remains, notwithstanding, controversial. [12] Besides, there is a developing body of information published about the role of genomic and molecular biomarkers to predict prognosis following CRLM. [13] The clinical effect of Kirsten ras (KRAS) mutation status among patients with CRLM has accumulated considerable interest with data from clinical trials noticing its possible role as a prognostic biomarker. [14] A meta-analysis suggested that KRAS mutations were prognostic biomarkers associated with worse survival outcomes among CRLM patients undergoing hepatic resection. [15] Our gathering has demonstrated that KRAS G12V and G12S mutations of codon 12 were independent prognostic factors of worse overall survival. [16] In a different report, KAS codon 13 mutations, but not codon 12 mutations, was related to a higher risk for overall extrahepatic recurrence and lung-specific recurrence. [17] Thusly, data on specific KRAS mutations might assist with individualizing therapeutic and surveillance strategies for patients with resected CRLM. The optimal tumor-free margin width might even be influenced by underlying tumor biology. For example, although a 1-to 4-mm margin clearance in patients with wild-type Kirsten ras tumors was associated with improved survival, wider resection width did not give an extra survival advantage. In contrast, margin status, including a 1-cm margin, did not improve survival among patients with mutKRAS cancers. [18] As the matter of fact, an R0 margin just provided a survival advantage to patients with wild-type Kirsten ras cancers. Tumor biology and not surgical technique

determining prognosis. [19] Patients with CRLM are treated with 5-fluorouracil based chemotherapy commonly combined with oxaliplatin (FOLFOX) and/or irinotecan (FOLFIRI), as well as possibly targeted agents (i.e., bevacizumab, cetuximab, panitumumab, aflibercept, ramucirumab, or regorafenib).

### Results & Discussion

Response rates with fluorouracil-based regimens for metastatic disease range from 25%-50%. [20] Presently, the choice of systemic treatment for CLRM is large "generally applied" with either FOLFOX or FOLFIRI dependent on comorbidities (e.g., diabetes, previous neuropathy, etc.) or anticipated toxicity. More "personalized" utilization of treatment is considerably more restricted (i.e., KRAS status for cetuximab, etc.) and still emerging (i.e., possible PD-1 therapy for MSI high patients).

Obstacles in the application of personalized medication in CRLM patients

Further enhancements in results among patients with CRLM will require increased individualization and personalized medicine in patients with CRLM in a multidisciplinary setting (Fig1). [21]

As the matter of fact, surgical oncology is more personalized now than any other time in recent as patients with "similar" diseases often should be treated with various treatments. Choice of treatment may depend on both clinical factors as well as surgeon provider-level characteristics. For example, patient age, tumor size and number, mutational status as well as the extent of resection, synchronous presentation, and the presence of extra-hepatic disease affect the choice of therapy. [9] Specialist subspecialty training and experience may likewise affect decision-making, with surgical oncology-trained clinicians being bound to use chemotherapy in the treatment plan. [9] These information highlights the need for providers and patients to be informed about the emerging different therapeutic options available to treat CRLM in the various individuals-specific settings. More randomization and comprehensive evidence-based to individualized, "personalized" CRLM treatments are needed to characterize what treatments work on specific subsets of patients. [21] To this point, clinical and biological studies are frequently not reproducible when tried in independent cohorts. [22] Because of the testing of a large number of various hypotheses and moderately small sample sizes, results from studies on that have examined whole-genome expression among patients with CRLM are regularly not reproducible. [22] In addition, various consensus documents, white papers, different forms of evidence on the

"personalization" of CRLM are confusing and often not well disseminated among surgeons. Although more and more researchers are advocating for "precision surgery and individually tailored therapy," the overall evidence for personalized therapy in the treatment of CRLM patients still cannot reach definitive conclusions that can be directly applied to the clinical setting.

### Conclusion

Multidisciplinary management of patients with CRLM has particularly added to survival. Developments in results are because of a large variety of factors including better systemic therapy, progress in perioperative care, as well as innovations in surgical therapy, as well as a shift in the paradigm of how "resectable" CRLM illness is defined. Although the most recent quite a few years have been described by these significant developments, future advances for patients with CRLM will rely upon a superior comprehension of genomics and molecular biology to promote with the portrayal of a specific tumor "identity" so that individualized therapy for each CRLM patient turns into the rule, and not the exception.

### Ethical Considerations

#### Compliance with ethical guidelines

This study was approved by the ethical committee of the Tehran University of Medical Sciences (TUMS). All the participants accepted enrollment in the study orally and all of the data that were gathered was considered confidential.

#### Funding

The authors received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

#### Authors' contributions

All authors equally contributed to preparing this article.

#### Conflict of interest


The authors declared no conflict of interest.

#### Acknowledgments

We would like to appreciate all those who helped us to conducted this study and provided us with valuable comments and kind consultations.



## Figure



**Figure 1. Personalized medicine in patients with CRLM in a multidisciplinary setting**

## Reference

- [1] Biankin AV, Hudson TJ. Somatic variation and cancer: therapies lost in the mix. *Human genetics*. 2011;130(1):79-91. <https://doi.org/10.1007/s00439-011-1010-0>
- [2] Kawamata H, Yamashita K, Kojo K, Ushiku H, Ooki A, Watanabe M. Discrepancies between the K-ras mutational status of primary colorectal cancers and corresponding liver metastases are found in codon 13. *Genomics*. 2015;106(2):71-5. <https://doi.org/10.1016/j.ygeno.2015.05.007>
- [3] House MG, Ito H, Gönen M, Fong Y, Allen PJ, DeMatteo RP, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. *Journal of the American College of Surgeons*. 2010;210(5):744-52. <https://doi.org/10.1016/j.jamcollsurg.2009.12.040>
- [4] Page AJ, Cosgrove DC, Herman JM, Pawlik TM. Advances in understanding of colorectal liver metastasis and implications for the clinic. *Expert review of gastroenterology & hepatology*. 2015;9(2):245-59. <https://doi.org/10.1586/17474124.2014.940897>
- [5] Pawlik TM, Abdalla EK, Ellis LM, Vauthey J-N, Curley SA. Debunking dogma: surgery for four or more colorectal liver metastases is justified. *Journal of gastrointestinal surgery*. 2006;10(2):240-8. <https://doi.org/10.1016/j.gassur.2005.07.027>
- [6] Zorzi D, Mullen JT, Abdalla EK, Pawlik TM, Andres A, Muratore A, et al. Comparison between hepatic wedge resection and anatomic resection for colorectal liver metastases. *Journal of Gastrointestinal Surgery*. 2006;10(1):86-94. <https://doi.org/10.1016/j.gassur.2005.07.022>
- [7] Lalmahomed ZS, Ayez N, van der Pool AE, Verheij J, IJzermans JN, Verhoef C. Anatomical versus nonanatomical resection of colorectal liver metastases: is there a difference in surgical and oncological outcome? *World journal of surgery*. 2011;35(3):656-61. <https://doi.org/10.1007/s00268-010-0890-9>
- [8] Moris D, Dimitroulis D, Vernadakis S, Papalampros A, Spartalis E, Petrou A, et al. Parenchymal-sparing hepatectomy as the new doctrine in the treatment of liver-

- metastatic colorectal disease: beyond oncological outcomes. *Anticancer research*. 2017;37(1):9-14.
- [9] Nathan H, Bridges JF, Cosgrove DP, Diaz LA, Laheru DA, Herman JM, et al. Treating patients with colon cancer liver metastasis: a nationwide analysis of therapeutic decision making. *Annals of surgical oncology*. 2012;19(12):3668-76. <https://ar.iiarjournals.org/content/37/1/9/tab-figures-data>
- [10] Spolverato G, Ejaz A, Azad N, Pawlik TM. Surgery for colorectal liver metastases: The evolution of determining prognosis. *World journal of gastrointestinal oncology*. 2013;5(12):207. <https://dx.doi.org/10.4251%2Fwjgo.v5.i12.207>
- [11] Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *New England Journal of Medicine*. 2012;366(26):2443-54. <https://doi.org/10.1056/NEJMoa1200690>
- [12] Copija A, Waniczek D, Witkoś A, Walkiewicz K, Nowakowska-Zajdel E. Clinical significance and prognostic relevance of microsatellite instability in sporadic colorectal cancer patients. *International journal of molecular sciences*. 2017;18(1):107. <https://doi.org/10.3390/ijms18010107>
- [13] Imai K, Allard M, Castro Benitez C, Vibert E, Sa Cunha A, Cherqui D, et al. Nomogram for prediction of prognosis in patients with initially unresectable colorectal liver metastases. *Journal of British Surgery*. 2016;103(5):590-9. <https://doi.org/10.1002/bjs.10073>
- [14] Andreatos N, Ronnekleiv-Kelly S, Margonis GA, Sasaki K, Gani F, Amini N, et al. From bench to bedside: Clinical implications of KRAS status in patients with colorectal liver metastasis. *Surgical oncology*. 2016;25(3):332-8. <https://doi.org/10.1016/j.suronc.2016.07.002>
- [15] Passiglia F, Bronte G, Bazan V, Galvano A, Vincenzi B, Russo A. Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. *Critical reviews in oncology/hematology*. 2016;99:150-7. <https://doi.org/10.1016/j.critrevonc.2015.12.015>
- [16] Margonis GA, Kim Y, Spolverato G, Ejaz A, Gupta R, Cosgrove D, et al. Association between specific mutations in KRAS codon 12 and colorectal liver metastasis. *JAMA surgery*. 2015;150(8):722-9.
- [17] Margonis GA, Kim Y, Sasaki K, Samaha M, Amini N, Pawlik TM. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. *Cancer*. 2016;122(17):2698-707. <https://doi.org/10.1001/jamasurg.2015.0313>
- [18] Margonis GA, Sasaki K, Andreatos N, Kim Y, Merath K, Wagner D, et al. KRAS mutation status dictates optimal surgical margin width in patients undergoing resection of colorectal liver metastases. *Annals of surgical oncology*. 2017;24(1):264-71. <https://doi.org/10.1245/s10434-016-5609-1>
- [19] Margonis GA, Sasaki K, Kim Y, Samaha M, Buettnner S, Amini N, et al. Tumor biology rather than surgical technique dictates prognosis in colorectal cancer liver metastases. *Journal of Gastrointestinal Surgery*. 2016;20(11):1821-9. <https://doi.org/10.1007/s11605-016-3198-8>
- [20] Adlard JW, Richman SD, Seymour MT, Quirke P. Prediction of the response of colorectal cancer to systemic therapy. *The lancet oncology*. 2002;3(2):75-82. [https://doi.org/10.1016/S1470-2045\(02\)00648-4](https://doi.org/10.1016/S1470-2045(02)00648-4)
- [21] Moris D, Pawlik TM. Personalized treatment in patients with colorectal liver metastases. *Journal of surgical research*. 2017;216:26-9. <https://doi.org/10.1016/j.jss.2017.04.013>
- [22] Sweeney TE, Haynes WA, Vallania F, Ioannidis JP, Khatri P. Methods to increase reproducibility in differential gene expression via meta-analysis. *Nucleic acids research*. 2017;45(1):e1-e. <https://doi.org/10.1093/nar/gkw797>

